WASHINGTON - AstraZeneca Plc said Wednesday that its coronavirus vaccine was 76 percent effective at preventing symptomatic illness in a clinical trial, slightly lowering the rate after facing questions in the United States over its data.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
